Cell-Based Therapy for Scarring Alopecia: What Patients Should Know

Cell-based therapy is not an established way to reverse scarring alopecia, and an active disease process generally makes hair transplantation unsafe to consider. The priority is to identify and control the inflammation that is damaging follicles; only after the condition has been quiet and stable for a sustained, individualized period should a specialist discuss whether surgery might be appropriate. “Quiescent” does not mean cured, and it is not a guarantee that the disease will never return.

Why scarring alopecia changes the treatment plan

Scarring, or cicatricial, alopecia describes hair loss in which inflammation damages follicles and replaces them with scar tissue. Unlike nonscarring hair loss, the affected follicles may be permanently lost, so treatment focuses first on stopping further damage rather than simply encouraging dormant follicles to grow. Several inflammatory and other conditions can cause hair loss, which is why the diagnosis matters (the American Academy of Dermatology’s overview of hair-loss causes).

A dermatologist—often one with experience in hair and scalp disorders—can assess symptoms and scalp changes, and may recommend a scalp biopsy or other evaluation when needed. Redness, scale, tenderness, burning, itching, or ongoing loss can be reasons to seek reassessment, but symptoms alone cannot establish whether the disease is active. Your clinician may compare examinations over time and, when appropriate, use tests to support the diagnosis and treatment plan.

This distinction is important because a transplant moves a patient’s existing follicles; it does not remove the underlying cause of scarring or create new follicles (the ISHRS patient guide to hair transplant surgery). Placing grafts into an actively inflamed area may expose them to the same damaging process, and surgery itself can add trauma to already affected skin. For these reasons, active scarring alopecia is generally a contraindication to transplantation.

What “quiescent” means before a transplant discussion

Quiescence means the disease appears inactive and the pattern of hair loss has remained stable—not that the condition has been erased. Before considering surgery, the treating dermatologist and a hair-restoration surgeon should agree that inflammation is controlled and that stability has lasted long enough to make planning reasonable. There is no single waiting period that fits every diagnosis and patient; do not rely on a universal timeline or a clinic’s promise that a short pause is sufficient.

Even when disease is quiet, candidacy is not automatic. Scarring can limit the amount and quality of donor hair, and the recipient area may not behave like unaffected scalp. The team should discuss the possibility of poor graft growth, renewed inflammation, further loss around transplanted hair, and the limits of what a procedure could accomplish. A Hair Transplant Clinic should coordinate with the dermatologist managing the alopecia rather than treating a stable-looking scalp as proof that the disease is inactive.

What cell-based treatments can—and cannot—do

“Cell-based therapy” is an umbrella term, not one standardized procedure. Investigational approaches include delivering cells or small tissue grafts, using cell-conditioned media, and using cell-derived extracellular vesicles such as exosomes. Research has largely examined pattern hair loss and other forms of hair thinning, not established treatment of active scarring alopecia. A 2023 systematic review included 15 studies and 653 participants, but protocols and cell types varied and the authors noted limitations such as small samples and short follow-up (the review in Cells).

That evidence cannot show that a cell product can safely restore follicles destroyed by scarring inflammation. Nor is there an established surgical procedure that grows new follicles in a laboratory and transplants them into a patient. Functional follicle regeneration would require follicles to cycle and connect with surrounding tissue and blood supply; this remains a research goal, not a clinical hair-restoration option (a review of follicle regeneration).

No stem-cell or regenerative product is FDA-approved for hair loss. The FDA also warns patients about unapproved regenerative medicine products; registration of a facility or an investigational application does not mean a product is approved (FDA patient information). Exosomes in particular are not an established treatment for hair loss, and human evidence remains preliminary. Ask any provider to specify exactly what is being administered, what evidence applies to your diagnosis, the known risks, and whether the treatment is part of a properly regulated clinical study (American Hair Loss Association information on exosomes).

Practical questions to ask your care team

Bring your diagnosis, treatment history, and a timeline of symptoms or visible changes to consultations. Ask how the clinician determined that the disease is inactive, how stability will be monitored, and what findings would postpone a transplant. Also ask who will manage your scarring alopecia before and after any procedure, what alternatives exist, and what outcome is realistic if some follicles have been permanently destroyed.

Be cautious if a provider presents cell therapy as a cure, suggests it can reactivate scarred follicles without supporting evidence, or recommends transplant surgery while inflammation is ongoing. Many Hair Transplant Clinics offer consultations, but the label alone does not establish expertise in inflammatory scalp disease. Look for a plan that puts disease control first and makes clear what is known, what remains uncertain, and who is responsible for follow-up.

Frequently Asked Questions

Can a hair transplant be done while scarring alopecia is active?

Generally, no: active inflammation can continue to damage follicles and may compromise a transplant. A dermatologist should assess and manage the disease before a surgeon considers reconstruction; the decision depends on the individual diagnosis and evidence of sustained stability.

How long does scarring alopecia need to be quiet before surgery?

There is no universal waiting period that applies to every type of scarring alopecia and every patient. The dermatologist and surgeon should determine an appropriate period based on the disease course, examination findings, and follow-up rather than relying on a fixed promise.

Can stem cells or exosomes regrow hair in scarred areas?

There is no established cell-based treatment proven to restore follicles destroyed by scarring alopecia, and no regenerative product is FDA-approved for hair loss (FDA patient information). Most published cell-based research concerns other forms of hair loss, so ask whether any claims apply specifically to your diagnosis and request clear information about risks and evidence.

The safest path is usually to confirm the diagnosis and control active disease before considering restoration. If your scalp becomes stable, a dermatologist and an experienced surgeon can help you weigh whether any procedure is appropriate—and what it can realistically achieve.